Market Tracker

06/09 5:38pm ET

Novo Nordisk A/S (NYSE:NVO)

158.07
Delayed Data
As of Jun 09
 -1.38 / -0.87%
Today’s Change
95.02
Today|||52-Week Range
172.97
+16.79%
Year-to-Date
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
Jun 09 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
Jun 05 / Zacks.com - Paid Partner Content
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
Jun 09 / Zacks.com - Paid Partner Content
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
Jun 05 / Zacks.com - Paid Partner Content
3 Reasons Why Growth Investors Shouldn't Overlook Novo Nordisk (NVO)
Jun 09 / Zacks.com - Paid Partner Content
Best Momentum Stocks to Buy for June 5th
Jun 05 / Zacks.com - Paid Partner Content
Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
Jun 09 / Zacks.com - Paid Partner Content
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
Jun 05 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
Jun 08 / Zacks.com - Paid Partner Content
Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.
Jun 05 / MotleyFool.com - Paid Partner Content
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
Jun 08 / Zacks.com - Paid Partner Content
New Strong Buy Stocks for June 5th
Jun 05 / Zacks.com - Paid Partner Content
Intercept (ICPT) Announces Positive Data From PBC Study
Jun 07 / Zacks.com - Paid Partner Content
Could Pfizer Have an Ozempic Killer on the Way?
Jun 05 / MotleyFool.com - Paid Partner Content
Merck (MRK) Sues US Government to Halt Drug Price Negotiations
Jun 07 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Jun 01 / Zacks.com - Paid Partner Content
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
Jun 07 / Zacks.com - Paid Partner Content
Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
May 31 / Zacks.com - Paid Partner Content
Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day
Jun 07 / Zacks.com - Paid Partner Content
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
May 31 / MotleyFool.com - Paid Partner Content
Bull of the Day: Novo Nordisk (NVO)
Jun 07 / Zacks.com - Paid Partner Content
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
May 31 / MotleyFool.com - Paid Partner Content
Ozempic is taking China by storm. Drugmakers are scrambling to boost supplies
Jun 06 / CNN.com
This Could Be Novo Nordisk's Next Big Weight-Loss Product
May 31 / MotleyFool.com - Paid Partner Content
Why Novo Nordisk Stock Bumped Higher Today
Jun 06 / MotleyFool.com - Paid Partner Content
5 Large Drug Stocks to Watch From a Thriving Industry
May 31 / Zacks.com - Paid Partner Content
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
Jun 06 / Zacks.com - Paid Partner Content
The Best Stocks to Invest $5,000 in Right Now
May 31 / MotleyFool.com - Paid Partner Content
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
Jun 06 / Zacks.com - Paid Partner Content
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
May 30 / Zacks.com - Paid Partner Content
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
Jun 05 / Zacks.com - Paid Partner Content
Better Dividend Stock: Eli Lilly or Novo Nordisk?
May 30 / MotleyFool.com - Paid Partner Content
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Jun 05 / Zacks.com - Paid Partner Content
This Pharma's Sales Are So Hot It's Trying to Curb Demand
May 30 / MotleyFool.com - Paid Partner Content